JP7179751B2 - Ｂ型肝炎コアタンパク質モジュレーターを作製する方法 - Google Patents

Ｂ型肝炎コアタンパク質モジュレーターを作製する方法 Download PDF

Info

Publication number
JP7179751B2
JP7179751B2 JP2019550235A JP2019550235A JP7179751B2 JP 7179751 B2 JP7179751 B2 JP 7179751B2 JP 2019550235 A JP2019550235 A JP 2019550235A JP 2019550235 A JP2019550235 A JP 2019550235A JP 7179751 B2 JP7179751 B2 JP 7179751B2
Authority
JP
Japan
Prior art keywords
compound
formula
give
group
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019550235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510059A5 (cg-RX-API-DMAC7.html
JP2020510059A (ja
Inventor
レピン リ，
リー ディー． アーノルド，
スリーニヴァサ レディ，
Original Assignee
アッセンブリー バイオサイエンシズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッセンブリー バイオサイエンシズ，インコーポレイテッド filed Critical アッセンブリー バイオサイエンシズ，インコーポレイテッド
Publication of JP2020510059A publication Critical patent/JP2020510059A/ja
Publication of JP2020510059A5 publication Critical patent/JP2020510059A5/ja
Application granted granted Critical
Publication of JP7179751B2 publication Critical patent/JP7179751B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019550235A 2017-03-13 2018-03-13 Ｂ型肝炎コアタンパク質モジュレーターを作製する方法 Expired - Fee Related JP7179751B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470560P 2017-03-13 2017-03-13
US62/470,560 2017-03-13
PCT/US2018/022100 WO2018169907A1 (en) 2017-03-13 2018-03-13 Process for making hepatitis b core protein modulators

Publications (3)

Publication Number Publication Date
JP2020510059A JP2020510059A (ja) 2020-04-02
JP2020510059A5 JP2020510059A5 (cg-RX-API-DMAC7.html) 2021-04-15
JP7179751B2 true JP7179751B2 (ja) 2022-11-29

Family

ID=61768549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550235A Expired - Fee Related JP7179751B2 (ja) 2017-03-13 2018-03-13 Ｂ型肝炎コアタンパク質モジュレーターを作製する方法

Country Status (9)

Country Link
US (2) US11040965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596070A1 (cg-RX-API-DMAC7.html)
JP (1) JP7179751B2 (cg-RX-API-DMAC7.html)
KR (1) KR102575605B1 (cg-RX-API-DMAC7.html)
CN (1) CN110612300B (cg-RX-API-DMAC7.html)
AU (1) AU2018236188B2 (cg-RX-API-DMAC7.html)
CA (1) CA3056696A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908475RA (cg-RX-API-DMAC7.html)
WO (1) WO2018169907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
BR112019018230A2 (pt) 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização
SG11202112590WA (en) * 2019-05-24 2021-12-30 Assembly Biosciences Inc Pharmaceutical compositions for the treatment of hbv
CN111333513B (zh) * 2020-04-17 2021-08-27 江苏恒沛药物科技有限公司 一种2,4-二氟-3-硝基苯甲酸的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017412A1 (en) 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
WO2015138895A1 (en) 2014-03-13 2015-09-17 Indiana University Research And Technology Corporation Hepatitis b core protein allosteric modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (ja) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピン誘導体
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
EP1937677A1 (en) 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
JP4042065B1 (ja) 2006-03-10 2008-02-06 健治 吉田 情報処理装置への入力処理システム
WO2008036139A2 (en) 2006-06-07 2008-03-27 The Regents Of The University Of California Inhibitors of mshc and homologs thereof, and methods of identifying same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
BRPI0916540B8 (pt) 2008-07-23 2021-05-25 Us Health inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
RU2519546C1 (ru) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CN104803880B (zh) * 2014-01-23 2017-11-21 广州喜鹊医药有限公司 一种具有神经保护作用的化合物及其制备方法和应用
KR20170018898A (ko) 2014-06-10 2017-02-20 바스프 에스이 살진균제로서의 치환된 [1,2,4]트리아졸 및 이미다졸 화합물
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
AU2017326356A1 (en) * 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017412A1 (en) 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
WO2015138895A1 (en) 2014-03-13 2015-09-17 Indiana University Research And Technology Corporation Hepatitis b core protein allosteric modulators

Also Published As

Publication number Publication date
KR102575605B1 (ko) 2023-09-05
CA3056696A1 (en) 2019-09-20
US11040965B2 (en) 2021-06-22
CN110612300B (zh) 2023-10-20
AU2018236188B2 (en) 2022-01-27
EP3596070A1 (en) 2020-01-22
CN110612300A (zh) 2019-12-24
SG11201908475RA (en) 2019-10-30
KR20190128675A (ko) 2019-11-18
US20200002325A1 (en) 2020-01-02
WO2018169907A1 (en) 2018-09-20
US20210380577A1 (en) 2021-12-09
JP2020510059A (ja) 2020-04-02
AU2018236188A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP2019151650A (ja) Ｂ型肝炎コアタンパク質アロステリックモジュレーター
TWI721016B (zh) B型肝炎核心蛋白質調節劑
ES2774318T3 (es) Inhibidores de bromodominio
CA2685215C (en) Compounds and methods useful for treating asthma and allergic inflammation
US20210380577A1 (en) Process for making hepatitis b core protein modulators
WO2018160878A1 (en) Cyclic sulfamide compounds and methods of using same
WO1997002244A1 (en) Heterocyclic carboxylic acid derivatives and drugs containing the same
WO2009076747A1 (en) Viral polymerase inhibitors
WO2008067644A1 (en) Inhibitors of hiv replication
CN109937201A (zh) 乙型肝炎核心蛋白调节剂
WO2022127699A1 (zh) 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN110066277B (zh) 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
WO2011082623A1 (zh) 一种非布索坦的制备方法
CN119285569A (zh) 一类五元氮杂环类衍生物及其制备方法和应用
HK40006155A (en) Aromatic heterocyclic substituted olefin compound, preparation method for same, pharmaceutical composition of same, and applications thereof
BR112016020895B1 (pt) Moduladores alostéricos da proteína do núcleo da hepatite b, seus usos, e composição farmacêutica
NZ723972B2 (en) Hepatitis b core protein allosteric modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221116

R150 Certificate of patent or registration of utility model

Ref document number: 7179751

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees